Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

NASDAQ: SHPH · IEX Real-Time Price · USD
0.432
+0.006 (1.43%)
At close: Jun 14, 2024, 12:23 PM
0.430
-0.003 (-0.58%)
After-hours: Jun 14, 2024, 7:39 PM EDT
1.43%
Market Cap 7.26M
Revenue (ttm) n/a
Net Income (ttm) -7.35M
Shares Out 16.79M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,307
Open 0.429
Previous Close 0.426
Day's Range 0.410 - 0.440
52-Week Range 0.350 - 1.270
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 13, 2024

About SHPH

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatm... [Read more]

Sector Healthcare
IPO Date Aug 31, 2022
Employees 8
Stock Exchange NASDAQ
Ticker Symbol SHPH
Full Company Profile

Financial Performance

Financial Statements

News

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the o...

23 days ago - GlobeNewsWire

Shuttle Pharma Provides First Quarter 2024 Corporate Update

GAITHERSBURG, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused...

4 weeks ago - GlobeNewsWire

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

GAITHERSBURG, Md., April 23, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the...

7 weeks ago - GlobeNewsWire

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

GAITHERSBURG, Md., April 03, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the...

2 months ago - GlobeNewsWire

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

GAITHERSBURG, Md., March 21, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused o...

3 months ago - PRNewsWire

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Shuttle Pharmaceuticals CEO Dr. Anatoly Dritschilo will be participating in the Emerging Growth Conference on Wednesday, March 6, 2024 at 11:25 am ET.

3 months ago - GlobeNewsWire

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

ROCKVILLE, Md. , Feb. 13, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("SHPH" or the "Company"), a discovery and development stage specialty pharmaceutical company focus...

4 months ago - PRNewsWire

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

ROCKVILLE, Md. , Jan. 23, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

5 months ago - PRNewsWire

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

ROCKVILLE, Md. , Jan. 8, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced they have received the 'Safe to Proceed' letter from the U.S. Foo...

5 months ago - PRNewsWire

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

ROCKVILLE, Md. , Dec. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced submission of an Investigational New Drug (IND) application with...

6 months ago - PRNewsWire

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Webcasted presentation to take place at 10:15am ET ROCKVILLE, Md. , Nov. 30, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pha...

7 months ago - PRNewsWire

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

ROCKVILLE, Md. , Nov. 14, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes f...

7 months ago - PRNewsWire

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

ROCKVILLE, Md. , Oct. 31, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

8 months ago - PRNewsWire

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

ROCKVILLE, Md. , Oct. 10, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

8 months ago - PRNewsWire

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Company remains on track to initiate the clinical trial in Q4 of 2023 ROCKVILLE, Md. , Sept. 25, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development...

9 months ago - PRNewsWire

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair

ROCKVILLE, Md. , Sept. 13, 2023  /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outc...

9 months ago - PRNewsWire

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

ROCKVILLE, Md. , Sept. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outco...

9 months ago - PRNewsWire

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

ROCKVILLE, Md. , Aug. 29, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

10 months ago - PRNewsWire

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes f...

10 months ago - PRNewsWire

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

ROCKVILLE, Md. , Aug. 3, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcome...

11 months ago - PRNewsWire

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

ROCKVILLE, Md. , May 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes fo...

1 year ago - PRNewsWire

Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

ROCKVILLE, Md. , May 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes fo...

1 year ago - PRNewsWire

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates

ROCKVILLE, Md. , March 22, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outco...

1 year ago - PRNewsWire

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update

ROCKVILLE, Md. , March 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes ...

1 year ago - PRNewsWire

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial

ROCKVILLE, Md. , March 9, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

1 year ago - PRNewsWire